Publications by authors named "Mark Sculpher"

Claim this Profile
G
Guiding Health Resource Allocation: Using Population Net Health Benefit to Align Disease Burden with Cost Effectiveness for Informed Decision Making.
Megha Rao, Simon Walker, Karl Claxton, Simon Bland, Jessica Ochalek, Mark Sculpher

Appl Health Econ Health Policy· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FRAME: Framework for Real-World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness - An Evaluation of Regulatory and Health Technology Assessment Decision Making.
Gianmario Candore, Claire Martin, Mack J Mills, Annabel Suter, Anna Lloyd, Mark Sculpher

Clin Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A Framework for Using Cost‑effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence.
Beth Woods, Alfredo Palacios, Mark Sculpher

Pharmacoeconomics· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England.
Beth Woods, Ben Kearns, Laetitia Schmitt, Dina Jankovic, Claire Rothery, Mark Sculpher

Appl Health Econ Health Policy· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence.
Beth Woods, Alfredo Palacios, Mark Sculpher

Pharmacoeconomics· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the natural history component of an early economic model for primary sclerosing cholangitis.
Christopher Bowlus, Cynthia Levy, Kris V Kowdley, Nandita Kachru, Sushanth Jeyakumar, Mark Sculpher

Orphanet J Rare Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life implications of plantar ulcers resulting from neuropathic damage caused by leprosy: An analysis from the trial of autologous blood products (TABLE trial) in Nepal.
Naomi Kate Gibbs, Jessica Ochalek, Indra Bahadur Napit, Dilip Shrestha, Pedro Saramago Goncalves, Mark Sculpher

PLoS One· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model.
Clive Pritchard, Lucie Kutikova, Richard Pitman, Kira Zhi Hua Lai, Hadi Beyhaghi, Mark Sculpher

Vaccines (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England.
Beth Woods, Ben Kearns, Laetitia Schmitt, Dina Jankovic, Claire Rothery, Mark Sculpher

Appl Health Econ Health Policy· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
Sue Harnan, Ben Kearns, Alison Scope, Laetitia Schmitt, Dina Jankovic, Mark Sculpher

Health Technol Assess· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using economic analysis to inform health resource allocation: lessons from Malawi.
Megha Rao, Dominic Nkhoma, Sakshi Mohan, Pakwanja Twea, Benson Chilima, Mark Sculpher

Discov Health Syst· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
Beth Woods, Laetitia Schmitt, Dina Jankovic, Benjamin Kearns, Alison Scope, Mark Sculpher

Health Technol Assess· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment.
Victoria Charlton, Michael DiStefano, Polly Mitchell, Liz Morrell, Leah Rand, Mark Sculpher

Health Econ Policy Law· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required.
Beth Woods, James Lomas, Mark Sculpher, Helen Weatherly, Karl Claxton

Health Econ· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Lancet Commission on prostate cancer: planning for the surge in cases.
Nicholas D James, Ian Tannock, James N'Dow, Felix Feng, Silke Gillessen, Mark Sculpher

Lancet· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial.
Carlos Chivardi, Holly Morgan, Mark J Sculpher, Tim Clayton, Richard Evans

Circ Cardiovasc Qual Outcomes· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
Nancy J Devlin, Tianxin Pan, Mark Sculpher, Mark Jit, Elly Stolk

Pharmacoeconomics· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of self-help group interventions for health in LMICs: a scoping review.
Jessica Ochalek, Naomi K Gibbs, Rita Faria, Joydeepa Darlong, Karthikeyan Govindasamy, Mark Sculpher

Health Policy Plan· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised trial of stable chest pain investigation: 3-year clinical and quality of life results from CE-MARC 2.
Colin C Everett, Colin Berry, Gerry P McCann, Catherine Fernandez, Catherine Reynolds, Mark Sculpher

Open Heart· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A qualitative study on the feasibility and acceptability of institutionalizing health technology assessment in Malawi.
Joseph Mfutso-Bengo, Faless Jeremiah, Florence Kasende-Chinguwo, Wingston Ng'ambi, Nthanda Nkungula, Mark Sculpher

BMC Health Serv Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing a Modeling Framework for Quantifying the Health and Cost Implications of Antibiotic Resistance for Surgical Procedures.
Heather Davies, Joel Russell, Angel Varghese, Hayden Holmes, Marta O Soares, Mark Sculpher

MDM Policy Pract· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the potential of HTA to inform resource allocation decisions in low-income settings: The case of Malawi.
Francesco Ramponi, Pakwanja Twea, Benson Chilima, Dominic Nkhoma, Isabel Kazanga Chiumia, Mark Sculpher

Front Public Health· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates.
Sakshi Mohan, Paul Revill, Stefano Malvolti, Melissa Malhame, Mark Sculpher

PLoS Negl Trop Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research.
Thomas Patton, Paul Revill, Mark Sculpher, Annick Borquez

Subst Use Misuse· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing the EQ-5D-5L Value Set for Uganda Using the 'Lite' Protocol.
Fan Yang, Kenneth R Katumba, Bram Roudijk, Zhihao Yang, Paul Revill, Mark Sculpher

Pharmacoeconomics· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis